PROF Archives - Page 2 of 9

Developments

Profound releases record Q3-2025 financial results; says “It’s Happening!”

Profound Medical (NASDAQ: PROF; TSX: PRN) announced that total revenues for the third quarter of 2025 were $5.3 million, representing year-over-year revenue growth of 87%. The gross margin for the third quarter of 2025...

November 13, 2025

Developments

Profound announces distribution agreement with Getz to bring TULSA-PRO to Australia and New Zealand

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has announced that it has entered into an exclusive distribution and supply agreement for its TULSA-PRO system with closely held Getz Healthcare, a leading distributor of...

November 12, 2025

Developments

Profound inks distribution agreement for TULSA-PRO and Sonalleve with Al Faisaliah in Saudi Arabia

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has announced that it has entered into an exclusive distribution and supply agreement for its TULSA-PRO and Sonalleve technologies in Saudi Arabia with Al Faisaliah Medical...

November 11, 2025

Developments

Profound regains distribution rights for TULSA-PRO in Canada

Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) has announced that it has regained exclusive distribution rights for TULSA-PRO in Canada from Knight Therapeutics (TSX: GUD). Under the agreement established with Knight...

November 11, 2025

Developments

Profound congratulates Busch Center for 500th TULSA procedure achieved

Profound Medical (NASDAQ: PROF; TSX: PRN) has unveiled new, real-world data from the internationally recognized Busch Center—marking the completion of 500 TULSA Procedures. This milestone highlights the versatility and...

October 16, 2025

Developments

Cook Medical’s launch of new iMRI division may help pave the way for wider and faster adoption of innovative procedures, like Profound’s TULSA

Cook Medical, a large family-owned medical device company known for its focus on minimally invasive treatment options, has launched a new Interventional Magnetic Resonance Imaging (iMRI) division, marking a significant...

July 29, 2025

Markets

Lake Street sees CMS’s proposed 2026 TULSA reimbursement as favorable

Lake Street Capital Markets senior research analyst, Ben Haynor, issued a research note today on Profound Medical (NASDAQ:PROF; TSX:PRN), reiterating his ‘buy’ rating and $11 target price on the company’s stock...

July 16, 2025

Developments

First BPH patient treated using Profound’s TULSA-PRO with TULSA-AI Volume Reduction

Profound Medical (NASDAQ: PROF; TSX: PRN) announced that the first commercial benign prostatic hyperplasia (BPH) treatment utilizing the TULSA-PRO system’s new TULSA-AI Volume Reduction Module was successfully conducted...

June 10, 2025

Developments

Leonard Wheeler, former NFL player, named global ambassador for Profound’s TULSA-PRO

Profound Medical (NASDAQ: PROF; TSX: PRN) today announced that it has entered into a consulting agreement with Leonard Wheeler—former NFL player, entrepreneur, author, corporate consultant, co-executive director of the...

June 4, 2025

Executive Moves

Accomplished medtech industry veteran, Laurie Vertuccio, joins Profound Medical as VP of Global Marketing

Laurie Vertuccio has joined Profound Medical (NASDAQ:PROF; TSX:PRN) as Vice President of Global Marketing. The TULSA procedure, performed using Profound’s TULSA-PRO system, has the potential of becoming a mainstream...

May 27, 2025

Tag - PROF

Profound releases record Q3-2025 financial results; says “It’s Happening!”

Profound announces distribution agreement with Getz to bring TULSA-PRO to Australia and New Zealand

Profound inks distribution agreement for TULSA-PRO and Sonalleve with Al Faisaliah in Saudi Arabia

Profound regains distribution rights for TULSA-PRO in Canada

Profound congratulates Busch Center for 500th TULSA procedure achieved

Cook Medical’s launch of new iMRI division may help pave the way for wider and faster adoption of innovative procedures, like Profound’s TULSA

Lake Street sees CMS’s proposed 2026 TULSA reimbursement as favorable

First BPH patient treated using Profound’s TULSA-PRO with TULSA-AI Volume Reduction

Leonard Wheeler, former NFL player, named global ambassador for Profound’s TULSA-PRO

Accomplished medtech industry veteran, Laurie Vertuccio, joins Profound Medical as VP of Global Marketing

Subscribe